FDA Approves Brentuximab Vedotin for Primary Cutaneous Anaplastic Large Cell Lymphoma

November 9, 2017 – Today, the U.S. Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received prior systemic therapy. Approval was based on the phase III, randomized, open-label, multicenter ALCANZA trial of brentuximab vedotin in patients with mycosis fungoides or pcALCL who had … (leggi tutto)